Heeke says the study would be open to people whose
tumors have evidence of HRD
like those found in this study, which includes bladder, breast, cervix, liver and bile duct, colorectal, endometrial, gastric / esophageal, head & neck, kidney, neuroendocrine, lung,
ovarian, pancreas, prostate, sarcoma, and thyroid cancers, as well as gastrointestinal stromal
tumors, glioma, melanoma and unknown primary cancers.
In addition, a growing number of immunotherapy clinical trials are in place to test this groundbreaking approach on other cancers
like lymphoma, multiple myeloma, and for solid
tumors, through trials in glioblastoma, mesothelioma, and
ovarian and pancreatic cancer.